The Ratio of Plasma Amyloid-β 1-42 over Serum Albumin Can Be a Novel Biomarker Signature for Diagnosing End-Stage Renal Disease-Associated Cognitive Impairment

Written By Yiran Gan
The Ratio of Plasma Amyloid-β 1-42 over Serum Albumin Can Be a Novel Biomarker Signature for Diagnosing End-Stage Renal Disease-Associated Cognitive Impairment - Hou et al. 2024

The Ratio of Plasma Amyloid-β 1-42 over Serum Albumin Can Be a Novel Biomarker Signature for Diagnosing End-Stage Renal Disease-Associated Cognitive Impairment

Publication Date: 2024.1.11

Authors: Hou Yi-Choua, Chueh Ti-I, Lu Kuo-Cheng, Liu Yi-Chien, Chen Tso-Hsiao, Liu Shing-Hwa, Chen Ruei-Ming

Journal: Journal of Alzheimer's Disease, vol. 97, no. 3, pp. 1393-1405, 2024

© 2024 Hou, Chueh, Lu, Liu, Chen, Liu and Chen

Journal of Alzheimer's Disease - IOS Press

Yiran Gan
Previous

Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial
Next

Thickness, Annealing, and Surface Roughness Effect on Magnetic and Significant Properties of Co40Fe40B10Dy10 Thin Films